Cargando…
Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat
BACKGROUND: The maturation inhibitor bevirimat (BVM) potently inhibits human immunodeficiency virus type 1 (HIV-1) replication by blocking capsid-spacer peptide 1 (CA-SP1) cleavage. Recent clinical trials demonstrated that a significant proportion of HIV-1-infected patients do not respond to BVM. A...
Autores principales: | Adamson, Catherine S, Sakalian, Michael, Salzwedel, Karl, Freed, Eric O |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873507/ https://www.ncbi.nlm.nih.gov/pubmed/20406463 http://dx.doi.org/10.1186/1742-4690-7-36 |
Ejemplares similares
-
The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles
por: Nguyen, Albert T, et al.
Publicado: (2011) -
Preservation
of HIV-1 Gag Helical Bundle Symmetry
by Bevirimat Is Central to Maturation Inhibition
por: Pak, Alexander J., et al.
Publicado: (2021) -
Development of Bevirimat (PA-457): first-in-class HIV maturation inhibitor
por: Allaway, Graham P
Publicado: (2006) -
HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
por: Fun, Axel, et al.
Publicado: (2011) -
Predicting Bevirimat resistance of HIV-1 from genotype
por: Heider, Dominik, et al.
Publicado: (2010)